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Abstract
Adrenocortical carcinoma (ACC) is an uncommon and heterogeneous disease and may present 
differently in children and adults. Management of ACC is dependent on disease stage and 
complete surgical resection is the only potentially curative treatment. The first and most 
extensively used adrenocortical cancer cell line, as model system to examine mechanisms 
controlling normal and pathologic function of adrenal cortex, was initially isolated in 1980. 
Although NCI-H295 maintained steroid capabilities and adrenocortical characteristics, the lack of 
new cell lines and animal models of ACC has hampered the progress and development of new 
therapies. In this review we provide description of cellular and patient-derived tumor xenograft 
(PDTX) models of ACC generated for the elucidation of the underlying pathogenic mechanisms 
and preclinical functional studies for this aggressive disease.
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1. Introduction
Adrenocortical carcinoma are highly heterogeneous tumors not only in terms of pathology 
and prognosis, but also with respect to underlying genomics, cellular signaling, steroid 
secretion as well as therapeutic responsiveness [1]. Consequently, there is an urgent need for 
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broad spectrum of preclinical tumor models reflecting disease heterogeneity to better 
elucidate the underlying molecular mechanisms and also enable the development of more 
personalized therapeutic approaches. While previously the establishment and 
implementation of novel human cell lines and xenograft models have remained an 
extraordinary challenge in this field, robust progress has been made over the past few years. 
Here we provide an overview on the models most commonly utilized as well as most recent 
developments on human models for adrenocortical carcinoma.
2. NCI-H295
The scarcity of preclinical models has remained a challenge for many years in the field of 
ACC with only one human adrenocortical cell line available (NCI-H295; [2]). The original 
patient tumor for this commonly used tumor model was obtained in 1980 from a 48-year-old 
woman who was initially evaluated for weight loss, acne, facial hirsutism, edema, diarrhea 
and recent cessation of menses [2]. After surgical resection of a large adrenal mass and 
subsequent processing of the respective tumor tissue as well as long-term culture over many 
years, Gazdar et al reported in 1990 on the first human adrenocortical cell line. Moreover, 
the group demonstrated that these cells retained the ability to produce all of the major 
adrenal steroids including corticosteroids, mineralocorticoids, androgens and estrogens [2]. 
Accordingly, until present, NCI-H295 is the most frequently implemented model in the 
context of steroidogenesis as well as steroidogenesis-related gene expression [3–5].
Interestingly, upon subcutaneous injection of 6×106 cells in athymic nude mice the tumor 
formation and take rate was detected in the range of 90% with a medium doubling time of 
12 days. No development of metastases was observed in these tumor-bearing mice ([6] and 
Figure 1). Histopathological examinations revealed characteristic features of human ACC as 
well as specific histological features similar to those of the original tumor [6]. Of note, upon 
intrasplenic injection of NCI-H295 cells and subsequent splenectomy, this tumor model can 
be furthermore utilized as ACC hepatic metastasis model [7, 8].
NCI-H295 cells harbor a large deletion in the TP53 locus (Table 1 and [9, 10]) and are also 
known to carry an activating CTNNB1 mutation [11, 12]. However, even though widely 
used as standard model for ACC, the analysis of the complete genetic landscape of NCI-
H295, based on whole-exome sequencing, has been just recently published [13].
Interestingly, this tumor xenograft model is characterized by dysregulation of the insulin like 
growth factor system such as overexpression of IGF2 and IGF-binding protein-2 [6]. In 
accordance with this notion various subsequent studies implemented the NCI-H295 in 
studies targeting IGF pathway in adrenal carcinogenesis [14–18] leading to first phase III 
randomized trial of a targeted small molecule inhibitor in ACC [19].
While such 2-D monolayer in vitro cultures and xenografts have truly been the workhorse of 
cancer biology mechanistic and functional research, the inherent lack of heterogeneity 
associated with these research models has contributed to modest success when translated 
into human clinical studies [19]. Over the last decade patient derived tumor xenografts 
(PDTXs) in nude mice have been developed across multiple human malignancies. In 
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comparison to xenografts, PDX models have been shown to retain heterogeneity seen in 
human tumors and present a promising in vivo platform to study tumor microenvironment 
and opportunity to develop novel rational personalized targeted therapies [20].
3. SJ-ACC3
Pediatric adrenocortical tumors are rare and frequently associated to germline TP53 
mutations or constitutional genetic abnormalities affecting chromosome 11p15 [21, 22] . A 
good outcome, as with most pediatric embryonal tumors, requires early diagnosis and 
complete surgical resection. Children with locally advanced or metastatic disease have a 
very poor prognosis, even with surgery and intensive chemotherapy [21]. Previously, 
adrenocortical cells were isolated from a tumor of a 11-month-old female patient with 
hypertension and hirsutism. Clonal cell populations were established and the one responsive 
to ACTH (HAC15) was further characterized and used for steroidogenesis studies [23]. 
Later on, subsequent analysis indicated that the clones were isolated from contaminated 
H295R cells, and therefore HAC15 cell line represents a subclonal population of H295R 
cells [24]. So far, the only established and characterized model for childhood ACC is 
represented by SJ-ACC3, derived from an 11-year-old boy with a right adrenal mass and not 
remarkable clinical signs and symptoms of virilization or hypercortisolism [25] (Figure 1 
and Table 1). The PDTX maintained the histology and pathomorphology of the primary 
tumor and DNA fingerprinting confirms the correct derivation of xenograft SJ-ACC3 (Table 
2). Molecular profiling of this model reveals that blood, primary tumor and xenograft model 
share the TP53 p.G245C mutation and whole genome sequencing analysis reveal a complex 
pattern of acquired mutations consistent with a more aggressive phenotype [26].
The most common combination therapy used in both childhood and adult ACC consists of 
cisplatin and etoposide with or without doxorubicin and mitotane [27–29]. In this pediatric 
PDTX model, a panel of commonly used chemotherapeutic agents were tested with cisplatin 
showing tumor growth inhibition, consistent with its use in frontline therapy for 
adrenocortical carcinoma [25]. However, the model was not responsive to etoposide or 
doxorubicin. In addition, the chemotherapeutic agent topotecan, a topoisomerase inhibitor 
showed cytostatic effects, with tumor growth inhibition in this model, suggesting topotecan 
as a potentially new agent for treatment of pediatric adrenocortical carcinoma [25]. 
However, to improve clinical responses and develop targeted therapies for pediatric patients 
with ACC, a spectrum of more effective preclinical models is urgently needed. Previous 
failure to obtain new models is contributed in part due to the rarity of the disease and the 
lack of success in implant of early stage. However, with the establishment of new tissue 
culture techniques and even more importantly collaborative efforts across the field the 
success is now potential.
4. MUC-1
In an attempt to broaden the preclinical armamentarium, many workgroups aimed in earlier 
years at the development of novel models for ACC. Unfortunately, NCI-H295 remained for 
many decades the only available human cell line of adrenocortical origin and represents, 
thus, also the most extensively studied tumor model in this field so far. However, in 2016 
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Hantel et al. successfully established a PDTX model and furthermore a human 
adrenocortical cell line from a surgical ACC sample (MUC-1, Figure 1 and [30]). During 
these studies MUC-1 xenografts, derived from a neck metastasis of an adult ACC patient, 
showed extraordinary engraftment properties and sustained tumor growth over several 
passages in the murine host. Molecular characterization of MUC-1 xenografts and 
subsequent comparison with the -to that date- available tumor models for ACC, revealed on 
mRNA and protein level Ki67, SF-1, EGF-receptor, IGF-1-receptor and IGF-2 profiles 
distinct from that of NCI-H295R and SJ-ACC3 [17, 30]. Moreover, the investigation of the 
subsequently established MUC-1 cell line demonstrated sustained proliferation and 
expression of adrenocortical markers including nuclear SF-1 and cytoplasmic 3βHSD 
immuno-positivity [30]. DNA fingerprinting of MUC-1 cells furthermore revealed a distinct 
short-tandem repeat (STR) profile different from that of NCI-H295R and SJ-ACC3 (Table 
2). Genetic analyses of known driver genes in the original patient tumor (also representing 
passage 1) revealed a somatic mutation in TP53 (a single G deletion [chr17:7,574,003 
(GRCh37/hg19)] resulting in a frameshift) while the tumor was devoid of mutations in any 
other known ACC driver genes (T91/L91 in [31] and [30]). This mutational status has been 
recently another time confirmed for the subsequently established MUC-1 cell line 
(unpublished data). More comprehensive genetic analyses in direct comparison with NCI-
H295 are currently underway.
In this context, it is also of great importance that first investigations reveal that therapeutic 
responsiveness differs between the tumor models NCI-H295, SJ-ACC3 and MUC-1. While 
NCI-H295 demonstrates good sensitivity over a wide variety of classical cytostatic as well 
as targeted agents ([17, 30, 32, 33], SJ-ACC3 [17, 25, 32] and MUC-1 ([17, 30, 33] as well 
as yet unpublished data from independent workgroups) tend to demonstrate a more moderate 
response or even drug resistant phenotype against single or combinatory approaches. Thus, 
this novel opportunity for a preclinical implementation of cell panels including both, rather 
sensitive as well as more drug resistant tumor models, might be of great benefit to decipher 
mechanisms of clinically frequently observed drug resistance in the future.
5. CU-ACC1 and CU-ACC2
In addition to MUC1, two new adult ACC pre-clinical models were recently reported by 
Kiseljak-Vassiliades and colleagues. Human CU-ACC1 and CU-ACC2 models were 
developed from metastatic perinephric and liver ACC lesions, respectively [34]. The 
development of PDTX models was achieved using fresh tissues at the time of surgical 
resection with immediate subcutaneous implantation into bilateral flanks of female athymic 
nu/nu mice (Figure 1). The initial CU-ACC1 and ACC-2 PDTX were passaged at 3 and 5 
months, respectively, with passage time intervals decreasing with subsequent passaging. To 
confirm the adrenocortical origin and match to human donor tissues, extensive profiling of 
PDX tissue was performed. STR assessment of CU-ACC1 and CU-ACC2 PDTX 
demonstrated 94% and 96% match with human tissue. Immunohistochemistry confirmed 
structural similarity between PDTX and human ACC tumors, as well as PDTX positivity for 
adrenocortical origin markers: SF1, inhibin-alpha and melanA [34].
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In contrast to PDTX development, the attempt to generate human ACC cell lines directly 
from CU-ACC1 and CU-ACC2 patients’ tissues collected at time of surgery was not 
successful, consistent with previous attempts to create human ACC cell lines. However, 
PDTX passaging provided additional opportunity for human ACC cell lines generation. 
Taking advantage of recently developed method, using irradiated mouse 3T3 feeder 
fibroblast (J2 strain) cells in presence of a Rho-associated protein kinase (ROCK) inhibitor 
([35], CU-ACC1 and CU-ACC2 were generated at the time of respective PDTX passaging. 
Fine 21-gauge needle aspiration method was used to obtain ACC tumor cells from PDTX 
tumors and then place onto the 3T3 feeder cell monolayer in the media containing multiple 
growth factor in addition to ROCK inhibitor. To confirm the origin of the newly developed 
in vitro models, the initial profiling of new ACC cells with STR showed 94% match with 
respective human tissue, and authentication against multiple STR databases confirmed that 
the new models were unique (Table 2). Species identification using newly developed ACC 
cell lines’ genomic DNA confirmed human origin. Similar to PDTX, the adrenocortical 
origin was also confirmed using immunocytochemical (ICC) staining for SF1. In addition to 
ICC, the secretome of newly developed cell lines was analyzed and demonstrated that while 
CU-ACC2 cells, similarly to patient tumor, were non-secretory, CU-ACC1 cell lines, 
originally from hyperaldosterone associated tumor, secreted cortisol and corticosterone [34].
Next generation sequencing of both newly developed ACC cell lines and PDTX provided 
global genomic and genetic signatures of these models. RNA sequencing confirmed the 
expression of ACC related transcripts and unsupervised global gene expression analysis 
confirmed the clustering of matched pre-clinical models. Exomic sequencing revealed 
CTNNB1 mutation in CU-ACC1 and TP53 in CU-ACC2 models (Table 1), with mutated 
allele being enriched in PDTX and cells compared to human tumor tissues. CU-ACC2 
models from a patient with Lynch syndrome and germline mutation in MSH2 gene, where 
the mutation was confirmed on DNA (exome) and protein (IHC) level in PDX and cell line.
Similarly, CU-ACC1 and CU-ACC2 models demonstrate unique molecular signatures which 
is also reflected in their growth characteristics and functional phenotype, as illustrated in a 
recent study where CU cell lines and H295R demonstrated differential sensitivity to MELK 
(maternal embryonic leucine kinase) inhibition [36].
7. Conclusion
While increasing the number of models begins to expand the research armamentarium in the 
field of adrenocortical carcinoma, further model development, such as 3-D cultures and 
PDX models, is critically needed to address tumor heterogeneity and the role of tumor 
microenvironment toward more rational therapies and drug combination development. With 
the development of new models we will be able to understand the cancer biology, biomarker 
development and preclinical evaluation of new drugs to provide and support evidence for 
clinical trials that aimed to help those suffering from this disease.
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Schematic illustration of the human adrenocortical tumor models NCI-H295, SJ-ACC3, 
MUC-1, CU-ACC1 and CU-ACC2. Of note, the pictures have been taken independently and 
at different timepoints after tumor induction.
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Table 1:
Different pathological and molecular characteristics of the human adrenocortical cell lines NCI-H295, SJ-

























11 Male Primary 
pediatric 
ACC
++++++ ≈33–60 % p. G254C WT Li-Fraumeni
MUC-1 24 Male Neck 
metastasis
+++ ≈30 % p.R210fs WT F None
CU-
ACC1
66 Female Perinephric 
metastasis
+++ ≈33–60 % WT p.G34R F
CU-
ACC2
26 Female Liver 
metastasis
+ ≈33–60 % p.G245S WT NF Lynch (Loss 
of MSH2)
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Table 2:
DNA profiling of adrenocortical cell lines determine by PCR-Single-Locus-Technology in comparison to the 
short-tandem-repeat profile of NCI-H295 as listed by ATCC
NCI-H295 SJ-ACC3 MUC-1 CU-ACC1 CU-ACC2
AMelogenin X XY X X X
CSF1PO 10,12 11 12 12 11, 12
D13S317 13 12,13 9 9, 13 13
D16S539 11 10,11 11, 14 9, 12 11, 12
D5S818 12 11 11 12 11, 12
D7S820 9,12 10 8, 10 8 8
TH01 9,3 6,9.3 9.3 7 9.3
TPOX 8 8,11 8 9, 11 8
vWA 17,18 16,19 16, 17 18 16, 18, 20
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